Abstract

The aim of the study is to assess the safety and efficacy of intrathecal administration of 17.5 mg Bupivacaine heavy (0.5%) and 26.25 mg Ropivacaine (0.75%) for orthopedic lower limb surgeries. The patients were belonging to physical status I and II as per ASA classification. The patients included in this study were from a wide range of age group 20 to 40 year of age and both sexes schedule for various operation for orthopaedic lower limb surgeries. 30 patients were divided into 2 groups of 15 each. Group I received Bupivacaine 17.5 mg and group II received Ropivacaine 26.25 mg. All the patient included in the study well subjected to through preoperative clinical examination in order to rule out any systemic disease. All the patients were monitor for NIBP, HR, SPO2 & ECG continuously till the end of surgery. Assessment of sensory block was done by pin prick and motor block using a modified Bromage score. Results: The mean pulse rate was found to be 85.48 minute (SD 6.08) in group I and 85.29 (SD 5.83) in group II. Intraopertive pulse rate in group I highest 101.20 and lowest 78.10. In group II highest pulse rate was 101.30 and lowest 77.70. The groups showed no statistically significance (P>0.05) changes in pulse rate at any point of time from 0 minute till the time of recovery. Thus excluding the possibility of tachycardia and bradycardia. Conclusion: Ropivacaine is newer amide type of local anaesthetic drug with significant enhanced safety profile and propensity to block sensory fibre more readily. Time of onset of sensory loss is early with Ropivacaine compared to Bupivacaine. Time of onset of motor loss is early with Bupivacaine compared to Ropivacaine. Duration of sensory and motor block are more with Bupivacaine as compared to Ropivacaine. No significant difference in both group for pulse rate and blood pressure. All this suggest that Ropivacaine has early onset of block and less duration as compared to Bupivacaine, so it is use as drug of choice for day care surgeries.

Description